+11 C°
Traffic jam:   0

Moderna shares down 35% from last week's report

13 November 2021
2 min.
Moderna shares down 35% from last week's report

Shares have fallen

Moderna (MRNA) shares have lost most of their growth since the start of 2021, last week's financial report was significantly worse than market analysts' forecasts and confirmed the fears of many investors.

Moderna (MRNA)'s share price fell sharply by 34.7% following the release of its Q3 2021 financial report, worsening the momentum of recent months.

Moderna shares have fallen 53.4% from their August 9 high, but their price is still more than 100% higher than at the start of 2021.

Reasons for the stock's decline

A number of factors contributed to Moderna's share fall. Given that Moderna Spikevax vaccine from Covid-19 is the company's only product, it is heavily dependent on its sales. This has investors worried amid competitive pressure from Pfizer (PFE) and other manufacturers of coronavirus vaccines. The emergence of effective anti-COVID-19 tablets from Merck (MRK) and Pfizer has also been reflected in a decline in the shares of many vaccine manufacturers.

The latest financial report was a disappointment, as was the news that Moderna's COVID-19 vaccine for children will be approved later than Pfizer's similar vaccine for children. Moderna Chief Medical Officer Dr Paul Burton said on Thursday that recent studies of the COVID-19 Spikevax vaccine showed a higher risk of myocarditis (a rare inflammation of the heart) in men under the age of 30 than the Pfizer vaccine. Data from France on men aged 12 to 29 showed that Moderna vaccine had 13.3 cases of myocarditis per 100,000 compared to 2.7 cases per 100,000 for the Pfizer vaccine.

On 4 November, Moderna reported disappointing sales and profit figures and lowered its annual sales forecast for its vaccines. All this on the back of Pfizer's excellent quarterly results and the competitor's announcement that Pfizer's market share of Covid-19 vaccines in the US is now 75%, down from 56% in April.

Moderna reported Q3 earnings of $7.70 per share, well below analysts' forecast of $9.05. Total revenues were $5bn, down as much as $1.2bn.

Moderna expects sales this year to be between $15 billion and $18 billion, down from a previous estimate of $20 billion. The company attributed the lower forecast to some shipments being pushed back to early 2022, as well as "prioritizing shipments to low-income countries"

Moderna said it had signed agreements to sell its Covid-19 vaccines worth $17bn in 2022 and said it expected sales in the commercial market to rise to $2bn next autumn.

Persons1 and Companies3 in the news

Chief Executive Officer of Moderna
1 place
1 place
2 place
3 place


Rating companies
197 Mention
Dow Jones
141 Mention
76 Mention
66 Mention
64 Mention
59 Mention
45 Mention


News from GlobalNY.biz is the freshest and most relevant information about high-profile events in the region. The task of the resource's news feed is to convey to readers with maximum accuracy and objectivity information about important events in business, politics, economy, healthcare, culture and other spheres of life in New York.
GlobalNY.biz news is a coverage of economic processes taking place in New York, the latest news of public life, incidents and an overview of political events. New York news is information about the activities of small and medium-sized businesses, the work of housing and communal services and utilities, the implementation of significant projects.
The site's journalists describe not only the life of the region, but also talk about the current state of the US economy. Everything you need to know about innovations in the field of industry and agriculture, economy and power is collected in the "News" section at GlobalNY.biz.
New York news quickly informs the reader, shows the real picture and opens up hot topics. Communication with government structures and business enables us to provide our readers with reliable, information-rich material. The main page of the portal contains the key news of New York!
Alena Potapova

Development Director
Died this year
Born this year